190 related articles for article (PubMed ID: 28983948)
1. Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab.
Fujimura T; Kambayashi Y; Hidaka T; Tamabuchi E; Otake E; Tono H; Mizuashi M; Furudate S; Aiba S
J Dermatol; 2018 Feb; 45(2):e35-e36. PubMed ID: 28983948
[No Abstract] [Full Text] [Related]
2. Posterior reversible encephalopathy syndrome in a melanoma patient with dabrafenib and trametinib treatment following immunotherapy.
Stefanou MI; Gepfner-Tuma I; Brendle C; Kowarik M; Meiwes A; Eigentler T; Müller A; Garbe C; Ziemann U; Tabatabai G; Forschner A
J Dtsch Dermatol Ges; 2020 Feb; 18(2):136-139. PubMed ID: 31814289
[No Abstract] [Full Text] [Related]
3. Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib.
Lacroix JP; Wang B
J Cutan Med Surg; 2017; 21(1):54-59. PubMed ID: 27624900
[TBL] [Abstract][Full Text] [Related]
4. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
5. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.
Fujimura T; Kambayashi Y; Tanita K; Sato Y; Hidaka T; Otsuka A; Tanaka H; Furudate S; Hashimoto A; Aiba S
J Dermatol; 2018 Jun; 45(6):735-737. PubMed ID: 29488243
[TBL] [Abstract][Full Text] [Related]
6. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
[TBL] [Abstract][Full Text] [Related]
7. Pyoderma Gangrenosum Under Dabrafenib and Trametinib for Metastatic Melanoma.
Saint-Jean M; Le Moigne M; Daguze J; Bossard C; Peuvrel L; Quéreux G; Dréno B
Acta Derm Venereol; 2018 Apr; 98(5):530-531. PubMed ID: 29362816
[No Abstract] [Full Text] [Related]
8. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
[TBL] [Abstract][Full Text] [Related]
9. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
Jansen YJ; Janssens P; Hoorens A; Schreuer MS; Seremet T; Wilgenhof S; Neyns B
Melanoma Res; 2015 Dec; 25(6):550-4. PubMed ID: 26512791
[TBL] [Abstract][Full Text] [Related]
10. Case of deep vein thrombosis in a patient with advanced malignant melanoma treated with dabrafenib and trametinib.
Wada N; Uchi H; Furue M
J Dermatol; 2018 Jul; 45(7):e173-e174. PubMed ID: 29430699
[No Abstract] [Full Text] [Related]
11. Acute intraventricular conduction disorder due to combination therapy with dabrafenib and trametinib for metastatic melanoma: Case report.
Yamamura K; Matsushita S; Aoki M; Kusumoto K
J Dermatol; 2018 May; 45(5):e120-e121. PubMed ID: 29178523
[No Abstract] [Full Text] [Related]
12. Fatherhood during dabrafenib and trametinib therapy for metastatic melanoma.
Cocorocchio E; Pala L; Battaglia A; Gandini S; Peccatori FA; Ferrucci PF
Acta Oncol; 2018 Aug; 57(8):1131-1133. PubMed ID: 29526130
[No Abstract] [Full Text] [Related]
13. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab.
Minor DR; Puzanov I; Callahan MK; Hug BA; Hoos A
Pigment Cell Melanoma Res; 2015 Sep; 28(5):611-2. PubMed ID: 25996827
[No Abstract] [Full Text] [Related]
14. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
15. Apparent darkening of scalp hair related to pili multigemini Following dabrafenib and trametinib.
Avila C; Hoffman K; Milani-Nejad N; Pootrakul L
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155032
[TBL] [Abstract][Full Text] [Related]
16. Acute heart failure as a result of granulomatous myocarditis: case report on a patient with metastatic melanoma treated with dabrafenib and trametinib.
Winkler JK; Buder-Bakhaya K; Ellert E; Herpel E; Martens UM; Enk A; Hassel JC
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e31-e32. PubMed ID: 28695986
[No Abstract] [Full Text] [Related]
17. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
18. Facing the challenges of new melanoma-targeted therapies: Treatment of severe fevers associated with dabrafenib/trametinib combination therapy.
Lindsay JN; Barras M
J Oncol Pharm Pract; 2015 Aug; 21(4):293-5. PubMed ID: 24664475
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide, dabrafenib mesylate, and trametinib dimethyl sulfoxide.
Hussar DA; Kaminski JL
J Am Pharm Assoc (2003); 2013; 53(5):550-8. PubMed ID: 24030134
[No Abstract] [Full Text] [Related]
20. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
